Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS

Experimental Neurology

Volumn 206, Issue 2, 2007, Pages 288-295

  Habisch, Hans Jörg ^a   Schwalenstöcker, Birgit ^a   Danzeisen, Ruth ^a   Neuhaus, Oliver ^b   Hartung, Hans Peter ^b   Ludolph, Albert ^a  

^a UNIVERSITY OF ULM   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Amyotrophic lateral sclerosis; Copaxone ; Cu Zn superoxide dismutase; Glatiramer acetate; SOD1 G93A

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; CYTOKINE; FREUND ADJUVANT; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 4; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; IMMUNOREGULATION; MALE; MOTOR PERFORMANCE; MOUSE; MOUSE STRAIN; NONHUMAN; OUTBRED STRAIN; PRIORITY JOURNAL; SPLEEN; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; T LYMPHOCYTE; VACCINATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE DOSAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, TRANSGENIC; MYELITIS; PARALYSIS; PEPTIDES; SUPEROXIDE DISMUTASE; SURVIVAL RATE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 34447632205     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.05.007     Document Type: Article

References (19)

1. Aharoni R., Kayhan B., Eilam R., Sela M., and Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14157-14162
2. Alexander G.M., Erwin K.L., Byers N., Deitch J.S., Augelli B.J., Blankenhorn E.P., and Heiman-Patterson T.D. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res. Mol. Brain Res. 130 (2004) 7-15
3. Alexianu M.E., Kozovska M., and Appel S.H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57 (2001) 1282-1289
4. Angelov D.N., Waibel S., Guntinas-Lichius O., Lenzen M., Neiss W.F., Tomov T.L., Yoles E., Kipnis J., Schori H., Reuter A., Ludolph A., and Schwartz M. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4790-4795
5. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S.R., Przedborski S., and Gendelman H.E. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9435-9440
6. Dal Canto M.C., and Gurney M.E. A low expressor line of transgenic mice carrying a mutant human Cu,Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Acta Neuropathol. (Berl.) 93 (1997) 537-550
7. Danzeisen R., Schwalenstoecker B., Gillardon F., Buerger E., Krzykalla V., Klinder K., Schild L., Hengerer B., Ludolph A., Dorner-Ciossek C., and Kussmaul C. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-l-propylamino-benzathiazole dihydrochloride]. J. Pharmacol. Exp. Ther. 316 (2006) 189-199
8. Farina C., Then Bergh F., Albrecht H., Meinl E., Yassouridis A., Neuhaus O., and Hohlfeld R. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 124 (2001) 705-719
9. Franciotta D., Zardini E., Bergamaschi R., Andreoni L., and Cosi V. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment. J. Neurol., Neurosurg. Psychiatry 74 (2003) 123-126
10. Goodin D.S., Frohman E.M., Garmany Jr. G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., and van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 (2002) 169-178
11. Gordon P.H., Doorish C., Montes J., Mosely R.L., Diamond B., Macarthur R.B., Weimer L.H., Kaufmann P., Hays A.P., Rowland L.P., Gendelman H.E., Przedborski S., and Mitsumoto H. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 66 (2006) 1117-1119
12. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
13. Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., and Hall E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39 (1996) 147-157
14. Hall E.D., Oostveen J.A., and Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23 (1998) 249-256
15. Henkel J.S., Engelhardt J.I., Siklos L., Simpson E.P., Kim S.H., Pan T., Goodman J.C., Siddique T., Beers D.R., and Appel S.H. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 55 (2004) 221-235
16. Hensley K., Floyd R.A., Gordon B., Mou S., Pye Q.N., Stewart C., West M., and Williamson K. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. 82 (2002) 365-374
17. Neuhaus O., Farina C., Wekerle H., and Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56 (2001) 702-708
18. Shibata N. Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuropathology 21 (2001) 82-92
19. Ziemssen T., Kumpfel T., Klinkert W.E., Neuhaus O., and Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125 (2002) 2381-2391